The tricks of lymphomas

Cancer cells create protective niches for themselves

05-Nov-2021 - Cellular immunotherapies have so far not been very effective against non-Hodgkin’s lymphoma. A team led by Armin Rehm of the MDC has discovered a possible reason. As they describe in “Cell Reports”, this cancer induces changes in the large blood vessels through which immune cells normally migrate ...

Nordic Nanovector: European Patent Granted for Betalutin or Humalutin in Combination With Anti-CD20 Antibodies for Treating NHL

04-Jun-2019 - Nordic Nanovector ASA announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma (NHL). The same patent has also been issued in ...

Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear

27-May-2019 - The German Institute for Quality and Efficiency in Health Care (IQWiG) has investigated whether patients suffering from non-Hodgkin lymphoma have (better) chances of recovery when stem cells from another person are transplanted. In its final report now presented, the Institute concludes that it ...

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma

04-Dec-2018 - In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ...

Shut-off switch for lymphoma

Important tumor suppressor discovered in immune cells

06-Dec-2017 - A safety switch that automatically stops the device for example before it overheats are built into many electrical appliances. The body's cells are also equipped with this kind of "emergency stop" functions. They make sure that a defective cell doesn't grow uncontrollably, becoming a tumor cell. ...

TSRI and St. Jude scientists study single 'transformer' proteins with role in cancer

23-Dec-2015 - A new study led by scientists at The Scripps Research Institute (TSRI) and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures. "We're studying basic biophysics, but we believe the complexity and rules we uncover for the physics ...

First medicine for rare blood cancer

EMA recommends Imbruvica for the treatment of Waldenstrӧm’s macroglobulinaemia

27-May-2015 - The European Medicines Agency (EMA) has recommended extending the use of Imbruvica (ibrutinib) to include the treatment of patients with Waldenstrӧm’s macroglobulinaemia, a rare blood cell cancer. Imbruvica is the first medicine that is recommended for this disease.The medicine is indicated for ...

Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)

05-Jul-2012 - The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).On 2 September 2011, Janssen-Cilag International NV ...

Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab

14-Jan-2011 - Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis.The phase II study in patients suffering from rheumatoid ...

MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program

29-Jun-2010 - MorphoSys AG and Xencor, Inc. announced the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by ...